Menu

Bristol’s Opdivo shows benefits in cancer immunotherapy trial

Ron Winslow

F. Stephen Hodi (Dana-Farber) led a study finding that more than one-third of advanced melanoma patients treated with Opdivo, a caner immunotherapy agent, have survived at least five years.

Read the full article